246 Shares in Danaher Co. (NYSE:DHR) Bought by Modus Advisors LLC

Modus Advisors LLC bought a new stake in shares of Danaher Co. (NYSE:DHR) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 246 shares of the conglomerate’s stock, valued at approximately $56,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. nVerses Capital LLC bought a new stake in shares of Danaher during the 2nd quarter valued at about $25,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher during the third quarter valued at approximately $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter worth approximately $55,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 2.2 %

Shares of Danaher stock opened at $234.84 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The firm has a market capitalization of $169.62 billion, a PE ratio of 44.82, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. The stock’s fifty day moving average is $236.58 and its 200-day moving average is $254.47.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.46%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

A number of research analysts recently commented on DHR shares. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research note on Thursday, October 31st. Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. Robert W. Baird decreased their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.05.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.